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AN ANALYSIS OF BULLETPROOF AS  
 
PROBABILISTIC GENOTYPING SOFTWARE FOR FORENSIC DNA  
 
ANALYSIS CASEWORK 
 
BRIANNA WYNEMA-ROCHELLE RANDOLPH  
 
ABSTRACT 
 Using computer systems for probabilistic genotyping on DNA evidence in 
forensic casework is beneficial as it allows a complete analysis of the data available for a 
wide range of profiles, a range that is limited when analyzed manually. One such 
software, Bulletproof, uses the exact method as the statistical foundation of its web-based 
interface to estimate the likelihood ratio of two hypotheses that explain the given 
evidence. In this investigation, the capability of Bulletproof was examined by analyzing 
the effects of evidence and reference sample template amount, injection time, and stutter 
filter utilization on likelihood ratio. In terms of likelihood ratio, deconvolution by the 
software is more efficient in cases in which evidence samples of high contrast ratios 
(such as 1:9 vs. 1:1) and low contributor count have high template, and when sample 
injection times are low. Reference sample template amount and injection time are less 
impactful than that of evidentiary samples. As with unknown samples, reference samples 
should be analyzed beforehand and artifacts removed for better deconvolution.   
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1. INTRODUCTION 
1.1 Overview 
Current human deoxyribonucleic acid (DNA) processing exploits specific 
components in our DNA in order to produce and analyze a profile for comparison in 
forensic casework. The generation of a DNA profile occurs in five steps: extraction, 
quantification, amplification, typing, and interpretation of the DNA present in a sample. 
During extraction, using heat and chemicals, the DNA is separated from the substrate, 
debris, and other cellular components present in the sample. The type of extraction 
method selected is dependent mostly on the type of sample, as well as the amount and 
quality of DNA estimated to be in the sample. Quantification serves to calculate how 
much human DNA, and also male DNA, is available in the sample. The quantification 
process is a real-time polymerase chain reaction, or qPCR, in which the concentration of 
DNA in a sample is estimated by the amount of cycles it takes to reach fluorescence 
threshold in the instrument1. This step is vital because the subsequent phase, 
amplification, is optimized at a target template value. If a sample is found to have too 
little or too much human DNA after qPCR, more of the sample can be extracted, or re-
extracted using a different technique or parameters, or the sample can be concentrated or 
diluted. QPCR also serves to determine if there is a component in the sample that could 
inhibit amplification, as there is an internal positive control (IPC) in the primer mix that 
is introduced to each sample. Quantification results include a concentration threshold 
value (CT) for this IPC, and if this value is higher than expected, then there is an 
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indication that the reaction maybe inhibited, and the sample can be re-extracted, diluted, 
or further purified to limit or remove the inhibition. 1,2.  
During amplification, specific regions of the genome, called loci, that are found in 
every human being are targeted and amplified into millions of copies via PCR. These 
sequences have characteristics, called alleles, that vary from person to person due to their 
hereditary nature. (Due to this nature, identical twins have the same characteristics and 
thus the same DNA profile, though there are recent methods to distinguish twin DNA in 
other ways3.) In common current practice, the loci used for forensic testing are composed 
of short tandem repeats (STR), which gives the entire five-step process the name STR 
analysis. STR are hypervariable areas of DNA that have sequences of repeating bases 
(typically four bases in length for forensic casework), and the number of repeating blocks 
of bases (repeats) dictate the allele4. For example, if Parent 1 donates a strand containing 
15 repeats of the sequence AGAT to their offspring at a specific location on the genome, 
i.e. at a specific locus, and Parent 2 donates a strand containing 16 repeats of the 
sequence AGAT, then the offspring will have a “15,16” genotype at that locus. The 
offspring would have two different alleles at a single locus, and would therefore 
considered to be heterozygous at this location. The kit used for PCR determines which 
loci are targeted for amplification in the samples. The amplified fragments are tagged 
with a fluorescent dye during PCR so that they can be isolated and identified in the next 
process. 
The amplicons are then “typed”, or separated from each other and detected, 
through a method that is most commonly capillary electrophoresis, or CE. During CE, the 
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specific sequence fragments are separated by size, i.e. number of base pairs (bp), and 
their fluorescent dye tag is excited by a laser. The resulting fluorescent emission 
information is compiled and uploaded to a computer program that organizes the 
information to form a DNA profile, in which the dye tagged-fragments are separated by 
color5. The alleles present in the fragments are organized by size, thus in increasing order 
of number of repeats. The alleles are represented as peaks on a spectrum, with the 
horizontal axis depicting base size and vertical axis depicting the relative fluorescent 
units (RFU) of the peak. The RFU of the peak corresponds to the relative intensity of the 
fluorescent emission of the fragments, and thus is proportionate to the amount of the 
tagged DNA sequence present in the sample6.  
After a DNA profile is generated, it must be interpreted. During interpretation, the 
analyst will assess the quality of the profile by looking at each sample’s size standard and 
look for any artifacts in the profile that are not believed to be a part of the contributor’s 
actual genome. For example, a common artifact seen in profiles is stutter. Stutter occurs 
during amplification when the DNA polymerases that create the fragment copies “slip” 
during the process and create a new fragment that is either one repeat longer or shorter 
(the latter being the most common) than the target fragment. This results in small peaks 
in a profile that are a repeat longer or shorter than the peaks that actually represent the 
alleles of the contributor, the most frequent being the latter, namely “backwards stutter”7. 
Generally, stutter peaks have a lower RFU than “true allele” peaks, and so an analysis 
level can be set in the software so that some stutter peaks can be excluded. This analytical 
threshold is also used to exclude most of the “noise”, or uninformative peaks that result 
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from operating the machinery itself8,9. Although typically analytical threshold falls 
between 30-100 RFU, the threshold ideally should be calculated after careful analysis of 
the baseline level of noise at each detected color9. A way to analyze stutter that is above 
this analytical threshold is to look at each locus individually, as the percentage level of 
the true allele’s RFU that stutter peaks are found is relatively conserved. In many cases, 
this percentage is around 10-15%, therefore peaks in stutter position, that have a ratio of 
around 0.10-0.15 to the proximal true alleles, are typically considered stutter. Stutter ratio 
is generally conserved from laboratory to laboratory as long as the amplification kit and 
CE instrument are conserved10. Other common artifacts include dye blobs, pull-up, 
spikes, and minus-A peaks.  
Another thing that affects profile interpretation is allelic dropout. Allelic dropout 
is the occurrence that an individual’s allele(s) at a location is below analytical threshold 
and is therefore not shown on the profile even though it exists in the individual’s 
genotype. It occurs when the sample is of relatively low quality (i.e. Low template, 
degradation, etc.) and/or one or both of the individual’s DNA strands are not amplified 
efficiently during PCR11. If low quality DNA is unavoidable, one way to account for 
allelic dropout is by validating a stochastic threshold. The stochastic threshold is the RFU 
level at which an analyst can safely assume that if an allele is above this threshold at a 
particular locus, then it’s sister allele would be at least above the analytical threshold7. 
Stochastic threshold is typically set after amplifying a series of samples of known 
genotypes of various concentrations and determining at what threshold sister alleles of 
heterozygous loci are detectable. However, there has been research conducted in order to 
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determine stochastic threshold more easily, such as using a logistic model incorporating 
PCR and CE parameters12.  
Profile interpretation is further complicated in the presence of two or more 
contributors to a sample, creating a mixed profile, also known as a mixture. In a mixture, 
there could be potentially more than two alleles at a single locus. Generally, the peak 
heights of the alleles belonging to each contributor is proportional to the amount of each 
contributor’s DNA that was amplified. For example, if two contributors donated DNA to 
a sample equally, typically there will be a 1:1 ratio of the total peak heights belonging to 
each contributor at a single locus. If contributor genotypes can be determined, possible 
major and minor contributors can be isolated from each other and treated as individual 
profiles. As stated before, this can become challenging in the presence of degradation, 
low template, allelic dropout, and artifacts13. Contributors can also share alleles (ex. One 
contributor is a 15,15 at a given locus and another contributor is a 15,16). Allele sharing 
can impede the process of estimating the number of contributors to the profile, a process 
that is recommended by the Scientific Working Group on DNA Analysis Methods14 and 
is necessary for certain statistical computations. The estimation of the number of 
contributors can be calculated by maximum allele count at each locus, a probabilistic 
approach incorporating allele frequencies15 or computer software16. 
 
1.2 Statistical Analysis 
Once an evidentiary profile is interpreted, the analyst can compare the profile to a 
reference, or known sample. In this way, individuals can be included or excluded as a 
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possible contributor to the DNA in the sample. An exclusion, according to John Butler in 
his textbook on DNA interpretation, occurs when “the genotype comparison shows 
profile differences that can only be explained by the two samples originating from 
different sources.”17 An inclusion means that the evidentiary sample contains all of the 
alleles possessed by the reference and all differences between the samples can be 
explained. However, evidentiary profiles can have vastly different components- amounts 
of artifacts, overall amount of DNA, peak height ratios, number of loci with alleles above 
stochastic threshold, etc.- and thus every inclusion does not hold the same weight. For 
instance, an inclusion to an evidentiary profile with only two loci with peaks above 
stochastic threshold will not have the same weight as one to a profile with sixteen loci 
with peaks above stochastic threshold. 
There are various methods utilized in current practice to determine the weight of 
evidence. One method is combined probability of inclusion (CPI), requires an inclusion 
of the reference to the evidence, and then determines what portion of the population is 
also included as a possible contributor to the evidence18. The benefit of CPI is that it does 
not require an assumption of the number of contributors for the calculation, and is 
relatively simple to calculate: 
CPI = (sum of allele frequencies at locus 1)2*(sum of allele frequencies at 
locus 2)2….*(sum of allele frequencies at locus N)2, with N being the 
number of detectable loci14 
CPI is limited, however, in that it cannot be used when allelic drop out is reasonable 
based on the data, and it also does not take advantage of peak heights, peak height ratios, 
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or genotypes of known persons19,20 Thus, CPI takes into account all permutations in a 
mixture and is very conservative, but it is not an accurate statistic as it adds genotypes 
that are not truly in the profile. 
Another method random match probability (RMP), which is defined by the 
Scientific Working Group on DNA Analysis Methods (SWGDAM) as “the probability 
that the DNA of a randomly chosen person has the same profile as the DNA of an 
evidentiary sample14.” RMP takes into account an estimated number of contributors and 
Hardy-Weinberg Equilibrium. The analyst determines all the possible genotypes that can 
be made with the alleles present at a single locus, calculates and combines the genotype 
frequencies according to heterozygosity or homozygosity:  
RMP: Heterozygous genotype = 2pq (with ‘p’ as the frequency of allele 1 
and ‘q’ as the frequency of allele 2) 
 Homozygous genotype =p2 + p(1-p)q  (with ‘q’ as the correctional 
value for any relatedness; q = 0.01 for the United States, 0.03 for 
some isolated populations)14  
All the RMP of the possible genotypes for that locus can be added together, and then the 
RMP of each locus can be multiplied together using the product rule to get the RMP of 
the profile. Both CPI and RMP can be presented either as a decimal, or more commonly, 
as “1 in 1/(decimal result) individuals.” For RMP, peak heights can be considered (using 
the restricted RMP method) in order to eliminate genotypes that are not probable with the 
data. Allelic dropout can also be considered with RMP, according to SWGDAM 
guidelines14.  
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 A method that includes more of the data presented in a profile than RMP is the 
estimation of likelihood ratios. The likelihood ratio (LR) is a comparison of the 
probabilities of two hypotheses given a certain set of data21. In the context of forensic 
analysis, the ratio is typically the hypothesis of the prosecution (Hp) over the hypothesis 
of the defense (Hd). The individual probabilities of the hypotheses themselves is less 
important in reporting than the ratio showing the probabilities relative to each other, like 
so:  
  LRHp,Hd(E): 
!(#	|	&')	!(#	|&))  , with ‘E’ being the evidentiary data21 
If LR < 1 and there are no other possible hypotheses than Hp and Hd, then the evidence 
supports Hd rather than Hp, meaning Hd is more likely to have occurred given the 
evidence21. The two hypotheses must be mutually exclusive, meaning one of them must 
be true and they cannot be true at the same time. Typically, Hp includes the hypothesis 
that the suspect is a contributor to the evidence, but can include unknown individuals as 
well.  
 
 
 
 
 
Figure 1. Example Loci of Two-Person Mixture Profile. At D13S317 locus, two peaks are shown 
for the alleles P and Q, with P having a larger peak height than Q.  
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Unlike CPI and RMP, LR can consider peak heights, peak heights relative to each 
other (the peak height ratio, PHR), an estimation of the number of contributors, the 
genotypes of those that can be assumed to be in the evidence, as well the genotypes of 
those debated to be a part of the evidence18. The analyst can choose to calculate an 
unrestricted or restricted LR. Unrestricted LR means that peak height ratios (PHR) are 
not considered when determining possibly genotype combinations, and thus combinations 
of alleles present at a locus are possible. Restricted LR means that PHR is taken into 
account, and combinations of alleles that are not probable given the PHR are not given as 
much weight14. The probabilities of Hp and Hd are calculations of the frequencies of the 
genotypes that support each hypothesis. For example, a two-person mixture has alleles P 
and Q at a locus (with frequencies of p and q, respectively) and the suspect has P,Q at 
this locus (Figure 1). Upon analysis of the entire profile, the ratio of contributors is 
determined to be 4:1. Hp is the hypothesis that the suspect is included as a contributor to 
the evidence as well as one other individual. In this case, the restricted LR numerator 
would be: 
  LR numerator: 1*p2 
The probability of the suspect is 1 because the Hp is that the suspect is 100% included, 
and the probability of the other unknown is the possible genotype combination that can 
be made with the suspect eliminated which is P,P. Hd is the hypothesis that the mixture is 
composed of two unknown individuals. In this case, the restricted LR denominator would 
be: 
  LR denominator: [p2 + p(1-p)q]*  [q2 + q(1-q)q ]+[2pq]* [p2 + p(1-p)q]   
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The denominator is the sum of all the probabilities of the possible genotype 
combinations14. In an unrestricted LR, the hypotheses would include all the possible 
genotypes, disregarding the 4:1 PHR.  
 In the example given, there was an estimation of only two contributors, there was 
a notable difference in peak heights, and only two alleles for one locus was analyzed. 
Calculating LR becomes increasingly more difficult to compute manually with an 
increase in contributors, a smaller difference in peak heights, inclusion of artifacts such 
as stutter, degradation, low template, and any other frequent but complicating 
components.  
 
1.3 Probabilistic Genotyping 
SWGDAM guidelines define probabilistic genotyping as “the use of biological 
modeling, statistical theory, computer algorithms, and probability distributions to 
calculate likelihood ratios (LR) and/or infer genotypes for the DNA typing results of 
forensic samples”22. Probabilistic genotyping computer systems are beneficial to DNA 
analysis because they allow a complete analysis of all the data available for a wide range 
of profiles, including low template and high contributor profiles. Also, according to 
Perlin, computer systems give a more accurate statistic, as human analysis tends to be 
more conservative by ignoring data under a certain threshold or ignoring loci that exhibit 
drop out characteristics23. Software can also analyze and predict the genotype of minor 
contributors that are less than 10% of the evidence sample23. Furthermore, using 
computer software for statistical analysis eliminates any subjectivity (as in human 
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analysis, the analyst needs to analyze the suspect’s DNA as well as the evidence) and 
considers more possible genotypes for unknown contributors in mixtures than a human 
analyst is capable of24.  
In recent years, many companies have developed probabilistic genotyping 
software in order to make DNA processing more efficient and thorough. Software 
generally uses of one of two models: semi-continuous (which does not consider peak 
heights or stutter when making calculations) or continuous (which makes assumptions 
based on peak height ratios)25. Software can also be based on various statistical methods, 
which can produce slightly different likelihood ratios for the same data set. For example, 
popular continuous method software STRmix™ and TrueAllele® both use the Markov 
chain Monte Carlo (MCMC) technique in order to estimate the most probable set of 
parameters- contributor genotype, degradation, amplification efficiency, etc.- for the 
data25,26. MCMC uses a “chain” to link the most probable parameters together using 
posterior probability distribution. On the other hand, another continuous software called 
EuroForMix uses an exact method that utilizes all possible contributor genotypes and 
parameters. The parameters are measured against their probability of occurrence given 
drop out, and only the parameters with extremely low probability are excluded27. This is 
different from MCMC as the MCMC “chain” assures that only the most probable out of 
the random parameters chosen are included. 
Bulletproof is another continuous method software with underlying algorithms 
based on EuroForMix. Instead of an external or downloadable software, Bulletproof’s 
interface is browser-based, and can be accessed from various operating systems28. There 
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is no need for a software or statistical calibration, and parameters can be set for the 
laboratory (accompanying every new data set) and adjusted for each run (i.e. changed for 
each new data set).  
In this study, the capability of Bulletproof was examined by observing the output 
it produced given various sets of data. The likelihood ratios given low template reference 
samples and low template evidence mixture samples, as well as a range of CE injection 
times for both reference samples and evidence mixtures samples were studied. Knowing 
that Hp was in fact the correct hypothesis, it was assumed that there would be a lower 
limit of template amounts and injections times for both reference and evidence samples to 
observe extremely high likelihood ratios. The study also compared the parameter 
estimates given by Bulletproof for what was believed to be in the mixtures compared to 
the actual contributor proportion.  
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2. METHODS 
 
2.1 Preparation of Profiles 
 In order to look at the effect of various evidence and reference characteristics on 
LR, DNA profiles were downloaded from a database created by Cotton et al 
(http://www.bu.edu/dnamixtures/pages/help/introduction)29. The database holds .fsa files 
of single source and mixture DNA profiles that were amplified at a variety of template 
amounts with various amplification kits, and separated on a 3130 genetic analyzer 
(Applied Biosystems, Foster City, CA) at multiple injection times according to the 
procedures and materials outlined by Cotton et al29. The mixture profiles contained 
material from multiple contributors at a range of ratios, changing the subject and contrast 
of the minor and major contributors.  
 Specific profiles- single source (Table 1) and mixtures (Table 2) were chosen for 
this study. All .fsa files selected from the database were amplified using the AmpFlSTR® 
Identifiler® PCR Amplification Kit (Life Technology, Carlsbad, CA). The single source 
profiles were from subjects A, B, and C, had been amplified at 0.0625, 0.125, 0.25, 0.5, 
and 1.0 ng, and injected at 2, 5 and 10 sec on the genetic analyzer. Two-contributor 
mixtures profiles using subjects A and B with ratios of 1:1 and 1:9 were isolated and had 
been amplified at 0.0625, 0.125, 0.25, 0.5, 1.0, and 4.0 ng, and injected at 2, 5, and 10 sec 
on the genetic analyzer. Three-contributor mixture profiles using subjects A, B, and C 
with ratios of 3:1.5:1(2) and 3:6:1 were isolated and had been amplified at 0.4, 1 or 1.7, 
and 3.5 or 4.0, and injected at 2, 5, and 10, sec on the genetic analyzer29.  
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Table 1. List of Chosen Single Source Profiles. Single source profiles from contributors A, B, 
and C amplified at 0.0625-1.0 ng using Identifiler® amplification kit and injected for 2-10 
seconds on a 3130 genetic analyzer.  
Sample Contributor Amount (ng) Injection (s) 
A 0.0625 A1 V1.0 Subject A 0.625 2 
A 0.0625 A1 V1.2 Subject A 0.625 5 
A 0.0625 A1 V1.3 Subject A 0.625 10 
A .125 A1 V1.0 Subject A 0.125 2 
A .125 A1 V1.2 Subject A 0.125 5 
A .125 A1 V1.3 Subject A 0.125 10 
A .25 A1 V1.0 Subject A 0.25 2 
A .25 A1 V1.1 Subject A 0.25 5 
A .25 A1 V1.2 Subject A 0.25 10 
A 0.5 A1 V1.0 Subject A 0.5 2 
A 0.5 A1 V1.2 Subject A 0.5 5 
A 0.5 A1 V1.3 Subject A 0.5 10 
A 1 A1 V1.0 Subject A 1 2 
A 1 A1 V1.2 Subject A 1 5 
A 1 A1 V1.3 Subject A 1 10 
B 0.0625 A1 V1.0 Subject B 0.625 2 
B 0.0625 A1 V1.2 Subject B 0.625 5 
B 0.0625 A1 V1.3 Subject B 0.625 10 
B .125 A1 V1.0 Subject B 0.125 2 
B .125 A1 V1.2 Subject B 0.125 5 
B .125 A1 V1.3 Subject B 0.125 10 
B .25 A1 V1.0 Subject B 0.25 2 
B .25 A1 V1.1 Subject B 0.25 5 
B .25 A1 V1.2 Subject B 0.25 10 
B 0.5 A1 V1.0 Subject B 0.5 2 
B 0.5 A1 V1.2 Subject B 0.5 5 
B 0.5 A1 V1.3 Subject B 0.5 10 
B 1 A1 V1.0 Subject B 1 2 
B 1 A1 V1.2 Subject B 1 5 
B 1 A1 V1.3 Subject B 1 10 
C 0.0625 A1 V1.0 Subject C 0.625 2 
C 0.0625 A1 V1.2 Subject C 0.625 5 
C 0.0625 A1 V1.3 Subject C 0.625 10 
C 0.5 A1 V1.0 Subject C 0.5 2 
C 0.5 A1 V1.2 Subject C 0.5 5 
C 0.5 A1 V1.3 Subject C 0.5 10 
C 1 A1 V1.0 Subject C 1 2 
C 1 A1 V1.2 Subject C 1 5 
C 1 A1 V1.3 Subject C 1 10 
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Table 2. List of Chosen Mixture Profiles. Two-contributor profiles from subjects A and B 
amplified at 0.0625-4.0 ng and three-contributor profiles from subjects A, B, and C amplified at 
0.4-4.0 ng using Identifiler® amplification kit and injected for 2-10 seconds on a 3130 genetic 
analyzer.  
Sample Contributor Amount (ng) 
Total 
Amount (ng) 
/ Minor 
Inj. (s) Ratio 
AB 0.0625 A1 1,1 V1.0 A, B 0.0625 0.031 2 1/1 
AB 0.0625 A1 1,1 V1.2 A, B 0.0625 0.031 5 1/1 
AB 0.0625 A1 1,1 V1.3 A, B 0.0625 0.031 10 1/1 
AB 0.125 A1 1,1 V1.0 A, B 0.125 0.063 2 1/1 
AB 0.125 A1 1,1 V1.2 A, B 0.125 0.063 5 1/1 
AB 0.125 A1 1,1 V1.3 A, B 0.125 0.063 10 1/1 
AB .25 A1 1,1 V1.0 A, B 0.25 0.125 2 1/1 
AB .25 A1 1,1 V1.2 A, B 0.25 0.125 5 1/1 
AB .25 A1 1,1 V1.3 A, B 0.25 0.125 10 1/1 
AB .5 A1 1,1 V1.0 A, B 0.5 0.250 2 1/1 
AB .5 A1 1,1 V1.2 A, B 0.5 0.250 5 1/1 
AB .5 A1 1,1 V1.3 A, B 0.5 0.250 10 1/1 
AB 1 A1 1,1 V1.0 A, B 1 0.500 2 1/1 
AB 1 A1 1,1 V1.2 A, B 1 0.500 5 1/1 
AB 1 A1 1,1 V1.3 A, B 1 0.500 10 1/1 
AB 4 A1 1,1 V1.0 A, B 4 2.000 2 1/1 
AB 4 A1 1,1 V1.2 A, B 4 2.000 5 1/1 
AB 4 A1 1,1 V1.3 A, B 4 2.000 10 1/1 
AB .0625 A1 1,9 V1.0 A, B 0.0625 0.006 2 1/9 
AB .0625 A1 1,9 V1.2 A, B 0.0625 0.006 5 1/9 
AB .0625 A1 1,9 V1.3 A, B 0.0625 0.006 10 1/9 
AB 0.125 A1 1,9 V1.0 A, B 0.125 0.013 2 1/9 
AB 0.125 A1 1,9 V1.2 A, B 0.125 0.013 5 1/9 
AB 0.125 A1 1,9 V1.3 A, B 0.125 0.013 10 1/9 
AB .25 A1 1,9 V1.0 A, B 0.25 0.025 2 1/9 
AB .25 A1 1,9 V1.2 A, B 0.25 0.025 5 1/9 
AB .25 A1 1,9 V1.3 A, B 0.25 0.025 10 1/9 
AB .5 A1 1,9 V1.0 A, B 0.5 0.050 2 1/9 
AB .5 A1 1,9 V1.2 A, B 0.5 0.050 5 1/9 
AB .5 A1 1,9 V1.3 A, B 0.5 0.050 10 1/9 
AB 1 A1 1,9 V1.0 A, B 1 0.100 2 1/9 
AB 1 A1 1,9 V1.2 A, B 1 0.100 5 1/9 
AB 1 A1 1,9 V1.3 A, B 1 0.100 10 1/9 
AB 4 A1 1,9 V1.0 A, B 4 0.400 2 1/9 
AB 4 A1 1,9 V1.2 A, B 4 0.400 5 1/9 
AB 4 A1 1,9 V1.3 A, B 4 0.400 10 1/9 
BAC 0.4 A1 1.5,3,2 
V1.0 
A, B, C 0.4 0.092 2 1.5/3/2 
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BAC 0.4 A1 1.5,3,2 
V1.2 
A, B, C 0.4 0.092 5 1.5/3/2 
BAC 0.4 A1 1.5,3,2 
V1.3 
A, B, C 0.4 0.092 10 1.5/3/2 
BAC 1 A1 1.5,3,1 V1.0 A, B, C 1 0.182 2 1.5/3/1 
BAC 1 A1 1.5,3,1 V1.2 A, B, C 1 0.182 5 1.5/3/1 
BAC 1 A1 1.5,3,1 V1.3 A, B, C 1 0.182 10 1.5/3/1 
BAC 4 A1 1.5,3,1 V1.0 A, B, C 4 0.72 2 1.5/3/1 
BAC 4 A1 1.5,3,1 V1.2 A, B, C 4 0.72 5 1.5/3/1 
BAC 4 A1 1.5,3,1 V1.3 A, B, C 4 0.72 10 1.5/3/1 
BAC 7 A1 1.5,3,1 V1.0 A, B, C 7 1.27 2 1.5/3/1 
BAC 7 A1 1.5,3,1 V1.2 A, B, C 7 1.27 5 1.5/3/1 
BAC 7 A1 1.5,3,1 V1.3 A, B, C 7 1.27 10 1.5/3/1 
BAC 0.4 A1 6,3,1 V1.0 A, B, C 0.4 0.04 2 6/3/1 
BAC 0.4 A1 6,3,1 V1.2 A, B, C 0.4 0.04 5 6/3/1 
BAC 0.4 A1 6,3,1 V1.3 A, B, C 0.4 0.04 10 6/3/1 
BAC 1.7 A1 6,3,1 V1.0 A, B, C 1.7 0.17 2 6/3/1 
BAC 1.7 A1 6,3,1 V1.2 A, B, C 1.7 0.17 5 6/3/1 
BAC 1.7 A1 6,3,1 V1.3 A, B, C 1.7 0.17 10 6/3/1 
BAC 3.5 A1 6,3,1 V1.0 A, B, C 3.5 0.35 2 6/3/1 
BAC 3.5 A1 6,3,1 V1.2 A, B, C 3.5 0.35 5 6/3/1 
BAC 3.5 A1 6,3,1 V1.3 A, B, C 3.5 0.35 10 6/3/1 
  
After the profiles were isolated from the database, they were viewed in 
GeneMapper IDX v1.4 (Applied Biosystems, Foster City, CA) software with no stutter 
filter and an analytical threshold of 30 RFU. Each profile was viewed to assess 
degradation, and any drop out in any of the loci for the profiles was noted. As the single 
source profiles were to be used as references in the Bulletproof software and could have a 
maximum of two alleles per locus, all artifacts – such as stutter, pull-up, minus A, etc. – 
were marked and removed from the profiles. The average peak height per locus for each 
profile was also calculated, taking the sum of all the peaks across the profile and dividing 
by the number of loci (i.e. 16 for Identifiler®). For implementation into the Bulletproof 
software, the profiles needed to be converted into tables in .csv format containing the 
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sample name, genetic marker, allele call, and peak height. For this reason, the genotype 
table of each profile with this information was exported into .csv format from 
GeneMapper IDX v1.4 after visualization and editing of the profiles. Because of this 
format – “comma-separated values” file- none of the sample names contained commas, 
as this would prevent implementation into the software. After the conversion, the files 
could be uploaded into the software as evidence and reference samples.   
 
2.2 Preparation of Software 
 Access to the Bulletproof probabilistic genotyping software was garnered from a 
virtual request on the eDNA consortium website (www.ednalims.com/probabilistic-
genotyping). After receiving approval of the request, a laboratory account was set up on 
the web-based interface, allowing for implementation of probabilistic genotyping on 
mock-cases using uploaded evidence and references. Bulletproof was relatively easy to 
use, as after an account was made within the browser, the program did not require any 
training samples to be implemented. Also, the primer manual as well as a phone tutorial 
from Dr. Kent Harman, President and CEO of Genetic Technologies, Inc., provided all 
the information needed to immediately start a case. 
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Figure 2. Laboratory Parameters for Mock-Cases Run on Software. Pre-set parameters were set 
for the probabilistic genotyping of evidence in the investigations.  
 
The laboratory parameters were set ahead of time for all of the investigations 
(Figure 2). Degradation was not found in any of the samples, however, based on trial runs 
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using the same profiles but varying the use of the degradation feature, its utilization 
produced more expected results. Therefore, the degradation parameter was checked so 
that the software could take this feature into account when deconvoluting the mixtures 
and calculating LR. The AT was set at 30 RFU and possible stutter peaks were ignored 
(i.e. the stutter parameter was not utilized) for all of the evidentiary profiles. The stutter 
parameter for Bulletproof is modelled after a stutter gamma distribution.  
 The mock-cases were created, and evidence and reference samples were uploaded 
according to the procedures outlined in the software primer28. The allele frequencies for 
the LR calculations were based on those listed by the National Institute of Technology 
(NIST) according to the Hispanic Population.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 20 
2.3 Likelihood Ratio and Evidence Template  
 All references were amplified at 0.5 ng and injected at 5 sec unless otherwise 
specified.  
In order to investigate the effect of increasing evidence template on LR, two-
contributor and three-contributor profiles with increasing total template were chosen as 
evidence in the mock-cases, holding constant the injection times (5 sec), the ratio of 
contributors, Hp, and Hd, and the laboratory parameters (Table 3).  
 
Table 3. List of Chosen Profiles for LR and Evidence Template Investigation. Two-contributor 
mixture profiles containing Subjects A and B at varying template (0.0625-4.0 ng) and varying 
ratios (1:1 and 1:9) and three-contributor mixture profiles containing Subjects A, B, and C at 
varying template (0.4-7.0 ng) and varying ratios (1.5:3:2(1) and 6:3:1). 
Run # Sample Contributor Amount (ng) Amount/Cont. Ratio 
1 AB 0.0625 A1 1,1 V1.2 A, B 0.0625 0.0315 1:1  
2 AB 0.125 A1 1,1 V1.2 A, B 0.125 0.0625 1:1  
3 AB 0.5 A1 1,1 V1.2 A, B 0.5 0.25 1:1 
4 AB 1 A1 1,1 V1.2 A, B 1 0.5 1:1 
5 AB 4 A1 1,1 V1.2 A, B 4 2.0 1:1 
6 AB 0.0625 A1 1,9 V1.2 A,B 0.0625 0.006, 0.0565 1:9 
7 AB 0.125 A1 1,9 V1.2 A, B 0.125 0.013, 0.112 1:9 
8 AB 0.5 A1 1,9 V1.2  A, B 0.5 0.05, 0.45 1:9 
9 AB  1 A1 1,9 V1.2 A, B  1 0.1, 0.9 1:9 
10 AB 4 A1 1,9 V1.2 A, B 4 0.4, 3.6 1:9 
11 BAC 0.4 A1 1.5,3,2 A1 V1.2 B, A, C 0.4 .092, .185, .123 1.5:3:2 
12 BAC 1 A1 1.5,3,1 A1 V1.2 B, A, C 1 .273, .545, .182 1.5:3:1 
13 BAC 4 A1 1.5,3,1 A1 V1.2 B, A, C 4 1.08, 2.18, .72 1.5:3:1 
14 BAC 7 A1 1.5,3,1 A1 V1.2 B, A, C 7 1.91, 3.81, 1.27 1.5,3,1 
15 BAC 0.4 A1 6,3,1 V1.2 B, A, C 0.4 .24, .72, .04 6,3,1 
16 BAC 1.7 A1 6,3,1 V1.2 B, A, C 1.7 1.02, .51, .17 6,3,1 
17 BAC 3.5 A1 6,3,1 V1.2 B, A, C 3.5 2.1, 1.05, .35 6,3,1 
18 BAC 7 A1 6,3,1 A1 V1.2 B, A, C 7 4.2, 2.1, .7 6,3,1 
  
The Hp for the runs including two-contributor evidence (runs 1-10 in Table 3) 
was conserved: subject A and subject B were contributors to the evidence. Hd for the 
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two-contributor evidence was conserved: subject A and an unknown individual were 
contributors to the evidence. The 1:9 A:B mixture evidence was also run with Hd 
including subject B and an unknown individual for comparison. The Hp for the runs 
including three-contributor evidence (runs 11-18 in Table 3) was conserved: subject A, 
subject B, and an unknown individual were contributors to the evidence. Hd for the three-
contributor evidence was conserved: subject A and two unknown individuals were 
contributors to the evidence. In this way, the likelihood of the presence of subject B given 
the evidence of varying DNA amount and ratio of contributors determined the final LR of 
Hp and Hd.  
 
2.4 Likelihood Ratio and Evidence Injection Time  
In order to investigate the effect of increasing evidence injection time on the 
genetic analyzer on LR, two-contributor and three-contributor profiles with increasing 
injection time were chosen as evidence in the mock-cases, holding constant the total 
template amount, the ratio of contributors, Hp, and the laboratory parameters (Table 4).  
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Table 4. List of Chosen Profiles for LR and Evidence Injection Time Investigation. Two-
contributor mixture profiles containing Subjects A and B and three-contributor mixture profiles 
containing Subjects A, B, and C at varying injection times (2, 5, and 10 seconds).  
Run Sample Contributor Inj. Time (s) Amount (ng) Amount/ 
Cont. 
Ratio 
1 AB 0.125 A1 1,9 
V1.0 
A, B 2 0.125 0.013, 
0.112 
1:9 
2 AB 0.125 A1 1,9 
V1.2 
A, B 5 0.125 0.013, 
0.112 
1:9 
3 AB 0.125 A1 1,9 
V1.3 
A, B 10 0.125 0.013, 
0.112 
1:9 
4 AB 1 A1 1,9 V1.0 A, B 2 1 0.1, 0.9 1:9 
5 AB 1 A1 1,9 V1.2 A, B 5 1 0.1, 0.9 1:9 
6 AB 1 A1 1,9 V1.3 A, B 10 1 0.1, 0.9 1:9 
7 BAC 0.4 A1 6,3,1 
V1.0 
B, A, C 2 0.4 .24, .72, 
.04 
6,3,1 
8 BAC 0.4 A1 6,3,1 
V1.2 
B, A, C 5 0.4 .24, .72, 
.04 
6,3,1 
9 BAC 0.4 A1 6,3,1 
V1.3 
B, A, C 10 0.4 .24, .72, 
.04 
6,3,1 
10 BAC 1.7 A1 6,3,1 
V1.0 
B, A, C 2 1.7 1.02, .51, 
.17 
6,3,1 
11 BAC 1.7 A1 6,3,1 
V1.2 
B, A, C 5 1.7 1.02, .51, 
.17 
6,3,1 
12 BAC 1.7 A1 6,3,1 
V1.3 
B, A, C 10 1.7 1.02, .51, 
.17 
6,3,1 
 
This investigation was performed in duplicate with two different Hd for the same 
dataset (Table 4). The Hp for the runs including two-contributor evidence (runs 1-6 in 
Table 4) was conserved: subject A and subject B were contributors to the evidence. The 
Hp for the runs including three-contributor evidence (runs 7-12 in Table 4) was 
conserved: subject A, subject B, and an unknown individual were contributors to the 
evidence.  
For the first set of runs, in the Hd for the two-contributor evidence, subject A and 
an unknown individual were contributors to the evidence. In the Hd for the three-
contributor evidence, subject A and two unknown individuals were contributors to the 
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evidence. In this way, the likelihood of the presence of subject B given the evidence from 
varying injection times using both small (0.125 or 0.4 ng) and large (1.0-1.7 ng) amounts 
of DNA determined the final LR of Hp and Hd.  
For the second set of runs, in the Hd for the two-contributor evidence, subject B 
and an unknown individual were contributors to the evidence. In the Hd for the three-
contributor evidence, subject B and two unknown individuals were contributors to the 
evidence. In this way, the likelihood of the presence of subject A -given the evidence 
from varying injection times using both small (0.125 or 0.4 ng) and large (1.0-1.7 ng) 
amounts of DNA- determined the final LR of Hp and Hd. 
 
2.5 Likelihood Ratio and Reference Template  
In order to investigate the effect of increasing reference template amount on LR, 
single source profiles (subjects A, B, and C) with increasing template amounts were 
chosen as references for the Hp in the mock-cases, holding constant the injection time (5 
sec), the evidence (three-contributor consisting of subjects B, A, and C at a 6:3:1 ratio at 
0.4 ng), Hd, and the laboratory parameters (Table 5).  
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Table 5. List of Chosen Profiles for LR and Reference Template Investigation. Single source 
profiles for subjects A, B, and C at varying template amounts (0.0625-1.0 ng).  
Run # Sample Contributor Amount (ng) 
1 A 0.0625 A1 V1.2 A 0.0625 
2 A 0.125 A1 V1.2 A 0.125 
3 A 0.25 A1 V1.2 A 0.25 
4 A 0.5 A1 V1.2 A 0.5 
5 A 1 A1 V1.2 A 1 
6 B 0.0625 A1 V1.2 B 0.0625 
7 B 0.125 A1 V1.2 B 0.125 
8 B 0.25 A1 V1.2 B 0.25 
9 B 0.5 A1 V1.2 B 0.5 
10 B 1 A1 V1.2 B 1 
11 C 0.0625 A1 V1.2 C 0.0625 
12 C 0.5 A1 V1.2 C 0.5 
11 C 1 A1 V1.2 C 1 
 
The Hp for the runs was conserved: subject A, subject B, and subject C were 
contributors to the evidence. However, one of the reference samples for one of the 
subjects for each run had a varying template amount. For example, in run #1 (Table 5), 
the references given to support Hp are sample A, which was amplified at 0.0625 ng and 
injected at 5 sec, sample B, and sample C. The difference between run #1 and #2 is the 
amount of subject A that can be used as a reference to support Hp -less DNA available 
increases the probability of allelic drop out, and thus less information for the software to 
work with when determining likelihood.  
Hd for the evidence was conserved: subject A, subject B, and an unknown 
individual are contributors to the evidence. In this way, the likelihood of the presence of 
subject C -given the evidence and varying DNA amount (and thus amount of information 
given) of the reference samples- determined the final LR of Hp and Hd. 
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2.6 Likelihood Ratio and Reference Injection Time 
In order to investigate the effect of increasing reference injection time on LR, 
single source profiles (subjects A, B, and C) with increasing injection times were chosen 
as references for the Hp in the mock-cases, holding constant the template amount (0.5 
ng), the evidence (three-contributor consisting of subjects B, A, and C at a 6:3:1 ratio at 
0.4 ng), Hd, and the laboratory parameters (Table 6).  
 
Table 6. List of Chosen Profiles for LR and Reference Injection Time Investigation. Single 
source profiles for subjects A, B, and C at varying injection times (2-10 sec). 
Run # Sample Contributor Inj. Time (Sec) 
1 A 0.5 A1 V1.0 A 2 
2 A 0.5 A1 V1.2 A 5 
3 A 0.5 A1 V1.3 A 10 
4 B 0.5 A1 V1.0 B 2 
5 B 0.5 A1 V1.2 B 5 
6 B 0.5 A1 V1.3 B 10 
7 C 0.5 A1 V1.0 C 2 
8 C 0.5 A1 V1.2 C 5 
9 C 0.5 A1 V1.3 C 10 
 
The Hp for the runs was conserved: subject A, subject B, and subject C were 
contributors to the evidence. However, one of the reference samples for one of the 
subjects for each run had a varying injection time. For example, in run #1 (Table 6), the 
references given to support Hp are sample A, which was amplified at 0.5 ng and injected 
at 2 sec, sample B, which was amplified at 0.5 ng and injected at 5 sec, and sample C, 
which was amplified at 0.5 ng and injected at 5 sec. The difference between run #1 and 
#2 is the injection time of subject A and thus the amount of information from subject A. 
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Hd for the evidence was conserved: subject A (sample A amplified at 0.5 ng and 
injected at 5 sec), subject B (sample B amplified at 0.5 ng and injected at 5 sec) and an 
unknown individual are contributors to the evidence. In this way, the likelihood of the 
presence of subject C -given the evidence and varying injection time (and thus amount of 
information given) of the reference samples- determined the final LR of Hp and Hd. 
 
2.7 Likelihood Ratio and Stutter Consideration 
 The effect of the utilization of Bulletproof’s stutter parameter on LR was 
examined, as well. Upon visualization of the two-contributor mixtures at a 1:9 ratio and 
the three-person mixtures, drop-out at one or more loci was observed. This drop-out 
could, and most likely would, affect the information the software had available to 
determine the likelihood of a certain contributor. Using a stutter filter in GeneMapper 
would further limit the information available, as peaks in the stutter position that might 
also host true alleles of a minor contributor would be lost. The stutter parameter in 
Bulletproof, if utilized, takes stutter into account when analyzing the evidence. This 
accountability has a greater impact on evidence with more extreme minor contributors.  
In order to investigate the effect of the software stutter parameter on LR, two-
contributor and three-contributor profiles with increasing total template were chosen as 
evidence in the mock-cases, holding constant the injection times (5 sec), the ratio of 
contributors, Hp, and Hd (Table 7).  
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Table 7. List of Chosen Profiles for LR and Stutter Consideration Investigation. Two-
contributor mixture profiles containing Subjects A and B at varying template (0.0625-4.0 ng) 
and three-contributor mixture profiles containing Subjects A, B, and C at varying template (0.4-
3.5 ng) run with stutter parameter utilized (Y) and not utilized (N).  
Run Sample Cont. Stutter Amount (ng) Ratio Amount (ng)/ Minor 
1 AB 0.0625 A1 1,9 V1.2 A, B Y 0.0625 1:9 0.006 
2 AB 0.125 A1 1,9 V1.2 A, B Y 0.125 1:9 0.0013 
3 AB 0.25 A1 1,9 V1.2 A, B Y 0.25 1:9 0.025 
4 AB 0.5 1,9 V1.2 A, B Y 0.5 1:9 0.05 
5 AB 1 1,9 V1.2 A, B Y 1 1:9 0.1 
6 AB 4 1,9 V1.2 A, B Y 4 1:9 0.4 
7 AB 0.0625 A1 1,9 V1.2 A, B N 0.0625 1:9 0.006 
8 AB 0.125 A1 1,9 V1.2 A, B N 0.125 1:9 0.0013 
9 AB 0.25 A1 1,9 V1.2 A, B N 0.25 1:9 0.025 
10 AB 0.5 1,9 V1.2 A, B N 0.5 1:9 0.05 
11 AB 1 1,9 V1.2 A, B N 1 1:9 0.1 
12 AB 4 1,9 V1.2 A, B N 4 1:9 0.4 
13 BAC 0.4 A1 6,3,1 V1.2 B, A, C Y 0.4 6:3:1 .04 
14 BAC 1.7 A1 6,3,1 V1.2 B, A, C Y 1.7 6:3:1 .17 
15 BAC 3.5 A1 6,3,1 V1.2 B, A, C Y 3.5 6:3:1  .35 
16 BAC 0.4 A1 6,3,1 V1.2 B, A, C N 0.4 6:3:1 .04 
17 BAC 1.7 A1 6,3,1 V1.2 B, A, C N 1.7 6:3:1 .17 
18 BAC 3.5 A1 6,3,1 V1.2 B, A, C N 3.5 6:3:1 .35 
 
 The Hp for the runs including two-contributor evidence (runs 1-12 in Table 7) 
was conserved: subject A and subject B were contributors to the evidence. Hd for the 
two-contributor evidence was conserved: subject A and an unknown individual were 
contributors to the evidence. The Hp for the runs including three-contributor evidence 
(runs 13-20 in Table 7) was conserved: subject A, subject B, and subject C were 
contributors to the evidence. Hd for the three-contributor evidence was conserved: 
subject A, subject B, and an unknown individual were contributors to the evidence. These 
mock-cases (one of the mixture samples as evidence, Hp, and Hd) were run once with the 
stutter parameter utilized and once with the stutter parameter unutilized. In this way, the 
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likelihood of the presence of subject C -given the evidence of varying DNA amount and 
whether or not stutter was accounted for- determined the final LR of Hp and Hd.  
 
2.8 Comparison of Software Mixture Composition vs True Mixture Composition 
In order to compare what Bulletproof estimated the contributor proportions were 
of given evidence to compared to the evidence’s actual proportions, the results of the LR 
and evidence template investigation was studied. The profiles utilized in that 
investigation (Table 3) had a wide range of template amounts and ratios that would allow 
for a comparison of mixture composition estimates.  
  Bulletproof gives results for both Hp and Hd: likelihood value, model validation, 
electropherogram fitted model, deconvolution, and parameter estimates for the 
contributors included in the hypotheses. For each run, the estimated proportion of each 
contributor (“Mix-Prop”) was compared to the actual proportion of each contributor 
based on the known ratios and total template amount.  
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3. RESULTS/ DISCUSSION 
 
The purpose of this thesis work was to explore the capability of the probabilistic  
genotyping software, Bulletproof, and to investigate how variation on profile quality, 
reference sample template, injection time, and stutter consideration affect the calculated 
likelihood ratio.  
The mock cases were run in Bulletproof with Hp and Hd as specified in each 
section. In the set-up of the runs, all prosecutor hypotheses intentionally explained the 
data more accurately than the defense hypotheses. Thus, a relatively large, positive LR 
for each run was expected. The actual numerical LR value was dependent on the variable 
features of the profiles.  
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3.1 Likelihood Ratio and Two-Contributor Evidence Mass 
 
Figure 3. Log(LR) with a Change in Two-Contributor Evidence Template Amount. Evidence 
samples containing contributors A and B with ratios of 1:1 and 1:9 respectively at an amplified 
mass of 0.0625, 0.125, 0.5, 1.0, and 4.0 ng DNA. LR = 𝐏(𝐄|𝐇𝐩.𝐀0𝐁	𝐏(𝐄|𝐇𝐝.𝐀0𝐔  , with “U” as an unknown 
contributor. (A:B = 1:9 also run with LR = 𝐏(𝐄|𝐇𝐩.𝐀0𝐁	𝐏(𝐄|𝐇𝐝.𝐁0𝐔) 
 
The cases shown in Figure 3 use two A, B mixtures at ratios of A:B = 1:1 and 
A:B = 1:9. For these comparisons, Hp = A + B and Hd = A + U. The A:B = 1:9 evidence 
was also analyzed with Hd = B + U. In this comparison of the impact of two-contributor 
evidence template amount on likelihood ratio, the highest LR was achieved when the 
evidence template amount was 0.5 ng for two contributors at a 1:1 ratio (log(LR)= 16.19) 
and between 0.5-1.0 ng at a 1:9 ratio (log(LR) = 18.82) with Hd = A + U. The software 
increasingly made more sense of the data (and thus was able to rightly assign Hp a higher 
likelihood value) when the amount of the evidence increased up to 1 ng at a ratio of 1:9. 
At 4 ng of template DNA, the LR decreased. This is explained by the marked increase in 
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off-ladder alleles due to pull-up, spikes, and stutter peaks above the AT that occurred in 
the profiles with the increases in template mass.  
The data shown in Figure 3 shows that deconvolution is more effective when 
evidence samples of high contrast ratios are used. It was also observed that large numbers 
of artifacts, such as found in the 4 ng profiles, resulted in significant negative changes to 
the LR. Thus, removing all known artifacts from profiles is necessary before Bulletproof 
can make sense of the data. The more overlapping “information” the software has- such 
as artifacts and contributor allele sharing of the same PH- the more difficult it is for 
deconvolution. The presence of artifacts masquerading as alleles increases the difficulty 
of determining genotypes.  
With the knowledge that Hp was the correct hypothesis, LR should be positive. In 
the instance that the LR is negative for the two-contributor evidence at a 1:1 ratio at 4 ng 
(Figure 3), this discrepancy can be attributed to the increased stutter and bleed-through 
artifacts overlapping with or adding to the number of “true” allele peaks, thus making it 
difficult to determine which peaks belong to subject A, B, or an unknown contributor. 
Visualization of the A:B 1:1 mixture at 4 ng in GeneMapper with no stutter filter applied 
revealed 40 artifacts across the profile, some of which are represented in Figure 4. With 
the stutter filter applied, 11 artifacts were observed. In GeneMapper, the A:B 1:9 mixture 
at 4 ng contained 19 artifacts without the stutter filter, and 1 artifact with the stutter filter. 
Upon re-analysis of the 4 ng samples at both 1:1 and 1:9 ratios with the Bulletproof 
stutter filter on, thus removing peaks below a certain threshold, the LR for both runs 
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increased significantly (Table 8). Note that the application of the stutter filter in either 
GeneMapper or Bulletproof would not remove non-stutter artifacts.  
 
 
Figure 4. Three Loci of the A:B 1:1 mixture at 4 ng in GeneMapper with No Stutter Filter 
Applied.  
 
Table 8. Comparison of LR given Software Stutter Filter on 4 ng Two-Contributor Evidence. 
Utilization of Bulletproof internal software filter on 4 ng evidence of both 1:1 and 1:9 ratios 
containing contributors A and B increased the LR as compared to non-utilization.  
Evidence Stutter Filter Ratio Log(LR) 
AB 4 ng No 1-1 -18.21 
AB 4 ng Yes 1-1 3.54 
AB 4 ng No 1-9 9.209 
AB 4 ng Yes 1-9 18.54 
  
Unlike the LR trend with Hd=A+U given the A:B 1:9 mixture, LR trend with 
Hd=B+U given the same evidence and same Hp (A+B) was much lower. In the Hd = 
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B+U, B is assumed to be present by both hypotheses (the prosecution and the defense), 
thus the LR is measuring the likelihood of the presence of subject A.  In the mixture, A is 
the minor contributor and has have overlapping peaks with major contributor alleles, 
confirmed in the electropherogram overlay in the software, which are more difficult to 
de-convolute than when A is known (Hd =A+U). 
 
3.2 Likelihood Ratio and Two-Contributor Evidence Injection Time 
 
Figure 5. Log(LR) with a Change in Two-Contributor Evidence Injection Time with Hd 
including Subject A. Evidence samples containing contributors A and B at a 1:9 ratio 
respectively at an amplified mass of 0.125 and 1.0 ng. All samples injected on 3130 at 2, 5, or 10 
seconds. LR = 𝐏(𝐄|𝐇𝐩.𝐀0𝐁	𝐏(𝐄|𝐇𝐝.𝐀0𝐔 , with “U” as an unknown contributor. 
 
 The comparisons shown in Figure 5 illustrate the impact of evidence injection 
times. For this comparison, Hp = A + B and Hd = A + U. The highest LR was observed 
from the 1 ng mixture injected at 5 seconds (logLR = 18.82). The scenario in which the 
10 second injection was the most beneficial for deconvolution occurred with the lowest 
evidence template amount of 0.125 ng. Ideal injection time should be determined based 
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on laboratory validation, as it is based on the mass of DNA amplified, the CE instrument, 
and the STR amplification kit. In cases of very low evidentiary template, longer injection 
times allow more DNA from the sample to enter the capillary for analysis, and thus 
produce higher peak heights across the profile30. For sample mixtures, it may be difficult 
to define an ideal injection time, since some mixture components may be present in a 
high amount and other mixture component(s) may be present in a low amount. 
 
Figure 6: Log(LR) with a Change in Evidence Injection Time with Hd including Subject B. 
Evidence samples containing contributors A and B at a 1:9 ratio at a total amount of 0.125 and 
1.0 ng. All samples injected on CE at 2, 5, or 10 seconds. LR = 𝐏(𝐄|𝐇𝐩.𝐀0𝐁	𝐏(𝐄|𝐇𝐝.𝐁0𝐔, with “U” as an 
unknown contributor.  
 
Using the same type of comparison with subject B as the known for the 
hypothesis of the defense (Figure 6), the highest LR was achieved when the two-
contributor evidence at 1 ng template was injected at 2 seconds (log(LR) = 10.55). As 
with Subject A in Hd, the 10 second injection time was the most beneficial for 
deconvolution for the lowest template amount of 0.125 ng.  
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When comparing the two Hd scenarios, Bulletproof could more efficiently 
deconvolute the evidence profile (produced a higher LR) when Hd included Subject A 
and observed the likelihood that B is present, and LRs were more varied when Hd 
included Subject B. The overall observation of the investigation is that when Hd includes 
subject A, the remaining alleles of the evidentiary profile were more easily attributed to 
subject B (the major contributor).  
 
3.3 Likelihood Ratio and Three-Contributor Evidence Mass 
 
Figure 7. Log(LR) with a Change in Three-Contributor Evidence Mass. Evidence samples 
containing contributors B, A, and C with a ratio of 1.5:3:1(or 2) and 6:3:1 at a total amount of 
0.4, 1.0, and 4.0(or 3.5). LR = 𝐏(𝐄|𝐇𝐩.𝐀0𝐁0𝐔𝐏(𝐄|𝐇𝐝.𝐀0𝐔𝟏0𝐔𝟐, with “U” as an unknown contributor. 
 
 The comparison shown in Figure 7 uses two three-contributor mixtures. The 
mixture ratios are B:A:C of 1.5:3:1(or 2) and 6:3:1. For both mixtures, Hp = A+B+U and 
Hd = A+U1+U2. In the comparison of three-contributor evidence mass, (Figure 7), the 
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highest LR was achieved when the evidence was 0.4 ng for three contributors at both 
1.5:3:2 (log(LR) = 8.295) and 6:3:1 (log(LR) = 17.18) ratios. Deconvolution became less 
effective as the mass amplified up to 1 ng and 3.5-4 ng at both ratios. This is explained by 
visualization of the profiles in GeneMapper, in which the 0.4 ng three-contributor profiles 
contained only true alleles and some stutter peaks. The higher template amounts 
contained more stutter peaks as well as pull-up, which increases the difficulty of 
deconvolution. For example, in GeneMapper, the B:A:C 1.5:3:2 mixture at 0.4 ng 
contained 2 stutter peaks across the profile. However, the mixture at 1.5 ng contained 21 
stutter as well as pull-up peaks.  
 These results give a conclusion that is compatible with the conclusion of the two-
contributor evidence; the three-contributor evidence results suggest deconvolution is 
negatively affected when evidence samples containing mixtures are amplified with too 
much DNA or analyzed using high injection times such that artifacts are created. For the 
three-contributor evidence, the only evidence that gave a positive LR was the lowest 
mass of 0.4 ng. Because the contributors to these three-person mixtures are known, we 
can see that there is extensive allele sharing. Thus, there are more alleles to deconvolute 
with their associated stutter peaks, and more possible genotype combinations. With an 
increase in mass, not only do the PH of the true alleles increase, but so does the PH of 
any artifacts, some of which will surpass the AT, making deconvolution more difficult. 
This gives insight into the importance of removing recognized artifacts from any profiles 
used with the software, i.e. analyst review before profile implementation and software 
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analysis. The results further highlight the need for adherence to the validated amplified 
target amount that is dependent on the STR kit used when conducting casework.  
 
 
3.4 Likelihood Ratio and Three-Contributor Evidence Injection Time 
 
Figure 8. Log(LR) with a Change in Three-Contributor Evidence Injection Time with Hd 
including Subject A. Evidence samples containing contributors B, A, and C at a 6:3:1 ratio at a 
total amount of 0.4 and 1.7 ng. All samples injected on CE at 2, 5, or 10 seconds. LR = 𝐏(𝐄|𝐇𝐩.𝐀0𝐁0𝐔𝐏(𝐄|𝐇𝐝.𝐀0𝐔𝟏0𝐔𝟐, with “U” as an unknown contributor. 
 
 The comparisons shown in Figure 8 illustrate the impact of evidence injection 
times. For this comparison, Hp = A+B+U and Hd = A+U1+U2. The highest LR was  
observed when the evidence at 1.7 ng was at 2 seconds (log(LR) = 17.70), although all 
three injection times produced similar LR. A log(LR) of ~17 was obtained from all 
injections of the 0.4 ng template and the two second injection of the 1.7 ng template. 
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Figure 9: Log(LR) with a Change in Evidence Injection Time with Hd including Subject B. 
Evidence samples containing contributors B, A, and C at a 6:3:1 ratio at a total amount of 0.4 
and 1.7 ng. All samples injected on CE at 2, 5, or 10 seconds. LR = 𝐏(𝐄|𝐇𝐩.𝐀0𝐁0𝐔𝐏(𝐄|𝐇𝐝.𝐁0𝐔𝟏0𝐔𝟐, with “U” as 
an unknown contributor. 
 
 Using the same type of comparison with subject B as the known for the 
hypothesis of the defense (Figure 9), the highest LR values were observed when the 0.4 
ng and 1.7 ng template samples were injected at 2 sec. When comparing the two Hd 
scenarios, Bulletproof deconvolutes the evidence similarly when either subject A or 
subject B was included as a contributor. Both comparisons showcase the sharp LR 
decrease with an increase in injection time for the 1.7 ng template sample, while LR was 
fairly conserved with a varied injection time for the 0.4 ng evidence. As stated with the 
two-contributor investigation, longer injection times allow more DNA from the sample to 
enter the capillaries and be detected, thus producing higher peak heights across the 
profile, including that of artifacts.  
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3.5 Likelihood Ratio and Reference Mass 
 
 
Figure 10. Log(LR) with a Change in Reference Mass. Reference samples for contributors A, B, 
and C at 0.0625, 0.125, 0.25, 0.5, and 1.0 ng using a 0.4 ng three-contributor (B-A-C) evidentiary 
profile of a 6-3-1 ratio respectively. LR = 𝐏(𝐄|𝐇𝐩.𝐀0𝐁0𝐂𝐏(𝐄|𝐇𝐝.𝐀0𝐁0𝐔, with “U” as an unknown contributor. 
 
 The comparisons shown in Figure 10 use a 0.4 ng three-contributor mixture at a 
ratio of B:A:C = 6:3:1 with reference profiles at various template amounts. For these 
comparisons, Hp = A + B +C and Hd = A + B + U. In this comparison of the impact of 
reference mass amount on likelihood ratio (Figure 10), the highest LR values were 
observed when the reference template amount was 0.5 ng and higher for subject A 
(log(LR) = 13.67), however there was a similar and consistent plateau for LR at after 0.25 
ng for the other two subjects (log(LR) = 12.32). The software increasingly made more 
sense of the data (and thus was able to rightly assign Hp a higher likelihood value) when 
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the amount of the references’ templates included all “true” alleles and no artifacts above 
the AT values (with stutter filters off).  
The effect of the reference sample’s template on LR was investigated because 
there may be cases where the only DNA reference available is from old or degraded 
samples. Or perhaps the reference is an alternate sample- also known as a 
psuedoreference- (in cases where a person of interest did not voluntarily give a known 
sample, but left behind on an item on which they deposited their DNA). In these 
circumstances, the amount of DNA used for analysis may not be ideal. The overall 
observation was that the minimum amount of DNA needed for a reference to achieve the 
highest LR for a three-contributor sample is 0.25 ng for known samples A, B, and C. 
Looking at the profiles in GeneMapper, there were less alleles available in the lowest 
template reference samples, thus less information for the software to analyze. For 
example, in the 0.0625 ng Subject A profile, there was one allele missing from 9 
heterozygous loci and 1 locus exhibiting total dropout for 11 total alleles missing from 
the profile. However, in the 0.25 ng Subject A profile, all 16 loci exhibited alleles and no 
alleles were missing from the profile.   
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3.6 Likelihood Ratio and Reference Injection Time 
 
Figure 11: Log(LR) with a Change in Reference Injection Time. Reference samples for 
contributors A, B, an C at 0.5 ng. All samples injected on 3130 at 2, 5, or 10 seconds. LR = 𝐏(𝐄|𝐇𝐩.𝐀0𝐁0𝐂𝐏(𝐄|𝐇𝐝.𝐀0𝐁0𝐔, with “U” as an unknown contributor. 
 
 The cases shown in Figure 11 use a 0.4 ng three-contributor mixture at a ratio of 
B:A:C = 6:3:1 with reference profiles at various CE injection times. For these 
comparisons, Hp = A + B +C and Hd = A + B + U. In this comparison of the impact of 
reference injection time on likelihood ratio, the highest LR was produced with subject A 
at all injection times (log(LR) = 13.67). For subjects B and C, approximately the same 
LR was produced for all three injection times (log(LR) = 12.32-13.67). This suggests, 
coupled with subject A’s LR variability with evidence injection time, that the reference 
sample of subject A impacts the deconvolution of the evidence and thus the resulting LR 
slightly more than the reference sample of the subject B and subject C.  
 However, an observation of the reference injection time investigation was that 
injection time made very little impact on LR, most likely due to the fact that all artifacts 
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needed to be removed beforehand on the reference samples. Thus, the information had all 
information needed for deconvolution at all injection times, without interference. These 
results, and the results of the previous investigations featuring the evidence mass and 
injection times as variables, outline the need for analysts to review both evidentiary and 
reference samples beforehand to label and exclude artifacts. Ideally, only true alleles are 
included in the information given to the software so that deconvolution can be as efficient 
as possible.  
 
3.7 Likelihood Ratio and Stutter Consideration 
 
Figure 12. Log(LR) with a Change in Stutter Parameter for a 2-Contributor Mixture. Evidence 
samples containing A and B contributors at a 1:9 ratio at 0.0625, 0.125, 0.25, 0.5, 1.0, and 4.0 ng 
total amount. LR = 𝐏(𝐄|𝐇𝐩.𝐀0𝐁	𝐏(𝐄|𝐇𝐝.𝐀0𝐔  , with “U” as an unknown contributor. 
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Figure 13. Log(LR) with a Change in Stutter Parameter for a 3-Contributor Mixture. Evidence 
samples containing B, A, and C contributors at a 6:3:1 ratio at 0.4, 1.7, and 3.5 ng total amount.  
LR = 𝐏(𝐄|𝐇𝐩.𝐀0𝐁0𝐂𝐏(𝐄|𝐇𝐝.𝐀0𝐁0𝐔, with “U” as an unknown contributor. 
 
 The effect of the application of the Bulletproof stutter parameter on LR was also 
examined. For a two-contributor evidence sample (Figure 12), the highest LR values 
were observed with the stutter parameter off (log(LR) = 18.82). However, the two lowest 
LR values were also observed with the stutter parameter off (log(LR) = 6.87, 9.21), and 
use of the Bulletproof stutter filter produced more consistent LR results for a two-
contributor sample. For a three-contributor evidence sample (Figure 13), use of the stutter 
filter produced consistently higher LR results for a three-contributor sample.  
 As stated previously, the stutter filter in GeneMapper has the benefit of removing 
some artifacts that are known not to be true alleles, with the cost of possibly removing 
true alleles that are in stutter position in a mixture sample. This project weighed this 
cost/benefit in the context of LR with and without the Bulletproof parameter utilized. The 
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overall observation was that using the stutter parameter produced more consistently 
positive LR estimations for both two- and three-contributor evidence samples. As 
Bulletproof states in their primer, and as supported here, using a stutter filter and/or their 
stutter parameter proves better for deconvolution even at the expense of missing 
information28. More comparisons would be needed to confirm whether this is consistently 
the case when the evidence in question represents a minor contributor with peak heights 
similar in RFU to stutter peaks. 
  
3.8 Comparison of Software Mixture Composition vs Actual Composition 
Table 9. Comparison of Software Mixture Composition Based on Hp to Actual Mixture 
Composition. Evidence samples containing contributors A and B with ratios of 1:1 and 1:9 at a 
total amount of 0.0625, 0.125, 0.5, 1.0, and 4.0 ng, and A,B, and C with a ratio of 1.5:3:1(or 2) 
and 6:3:1 at a total amount of 0.4, 1.0, 4.0(or 3.5), and 7 ng.  
Evidence  Actual 
Ratio 
Hp: Subj A 
Prop Est 
Hp: Subj B 
Prop Est 
Hp: Unknown 
Prop Est 
Estimated 
Ratio 
AB 0.0625 1:1 0.8416 0.1584 N/A ~8:2 
AB 0.125 1:1 0.5246 0.4754 N/A ~1:1 
AB 0.5 1:1 0.546 0.4454 N/A ~1:1 
AB 1 1:1 0.5545 0.4455 N/A ~1:1 
AB 4 1:1 0.5069 0.4931 N/A ~1:1 
AB 0.0625 1:9 5.48E-12 1 N/A ~0:1 
AB 0.125 1:9 0.2438 0.7562 N/A ~2:8 
AB 0.5 1:9 0.2237 0.7763 N/A ~2:8 
AB 1 1:9 0.2337 0.7663 N/A ~2:8 
AB 4 1:9 0.2076 0.7924 N/A ~2:8 
BAC 0.4 3:1.5:2 0.4176 0.2122 0.3702 ~4:2:4 
BAC 1 3:1.5:1 0.5829 0.268 0.1491 ~6:3:1 
BAC 4 3:1.5:1 0.3532 0.2473 0.3995 ~4:2:4 
BAC 7 3:1.5:1 0.3473 0.1563 0.4964 ~3:2:5 
BAC 0.4 3:6:1 0.3296 0.5283 0.1421 ~3:5:1 
BAC 1 3:6:1 0.2649 0.5731 0.162 ~3:6:2 
BAC 4 3:6:1 0.2921 0.4611 0.2468 ~3:5:2 
BAC 7 3:6:1 0.2643 0.3787 0.357 ~3:4:4 
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 Amongst the results output of the Bulletproof software, the estimated proportions 
of the contributors assumed in Hp are provided. These estimates were compared to the 
known proportions of each contributor in the two-contributor and three-contributor 
evidence samples (Table 9). The estimated ratios produced by Bulletproof (column 6) are 
very similar to the actual ratios of the evidence (column 2). There is greater discrepancy 
between the estimations and actual values with the lower template values (AB mixture at 
0.0625 ng and BAC mixture at 0.4 ng). Additionally, the software performed best on two-
contributor evidence (predicting the correct proportions for four out of five of the 1:1 
ratio samples), and produced similar ratios to the actual proportions of the three-
contributor evidence.  
 Having accurate (or close-to-accurate) evidence contributor proportion is 
important because with correct ratios/proportions, the software can more accurately 
understand the information given (i.e. peak heights, probability of allele sharing, 
probability of drop out, etc.) and can more accurately deconvolute the contributor 
genotypes to an evidence profile.   
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4. CONCLUSION 
 
The goal of this thesis was to investigate the capability of a specific probabilistic  
genotyping software in deconvoluting evidence and estimating likelihood ratio with 
specific changes in evidence or reference profiles. Probabilistic genotyping is rapidly 
becoming more common in DNA casework analysis in today’s time, and it is important 
for future cases, and in turn future trials, that the analyses are efficient and its results 
accurate. This study has shown the importance of using appropriate amounts of  DNA 
template for amplification and  also the importance of removing profile artifacts prior to 
software analysis. 
Additional work is needed to give a true estimation of the capability, and thus 
limits of the Bulletproof software. There were instances in the investigations in which LR 
was negative, meaning the hypothesis of the defense appeared to be more probable than 
the hypothesis of the prosecution. Knowing that all Hp were in fact more probable than 
Hd by design, this shows a realistic limitation of the software, as it still requires prior 
manual analysis of all samples.  An expansion of this study could perhaps use more 
evidentiary samples with a broader range of ratios, templates, and number of 
contributors.  
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